assume for sublingual administration, and although it acts faster than Marinol, which takes an hour and a half to two hours, always requires more time than that of smoked marijuana. In addition, given its unpleasant flavor, many patients do not may keep under the language for the time necessary to its absorption". And with regard to the safety? "In effect, the new derivatives may be much less sure of marijuana to smoke, because it will be possible to ingerirne quan- A Conference of Democratic Member Maurice Hinchey in favor of therapeutic marijuhana, Washington, May 2005. Titativi higher than needed. Any new derivative must have a "safety index acceptable". In the case of marijuana this index is unknown because it has never caused a death by overdose. It is estimated on the basis of extrapolations from animal data, which is an almost non-existent 20.000-40.000 [This digit indicates the ratio between the lethal dose and the therapeutic dose: more is high, the more the drug is considered safe, ndr.]. It is unlikely that the index of safety of a new derivative could be higher ". But you can not delete the effects psychoactive? "I am not convinced that the therapeutic benefits of hemp can always be separated from its psychoactive effects. I do not believe that this is desirable. There is to say that anyone who smokes cannabis frequently to reduce a chronic pain or a high intra-ocular pressure will have a "high" very limited or non-existent. Many patients suffering from serious chronic diseases report that cannabis makes them feel better in general and notice a slight improvement of mood. But if there really is some difference in dosage between the alleviation of symptoms and the effect psicoattivo, then it is important that patients have the possibility of dosing the amount of cannabis they need, and this is only possible by smoking it. For those who do not like the effect psicoattivo, you can always develop a derivative of cannabis without them". She also speaks of a field enhancement of human faculty. What are you referring to? "This is a field of action of cannabis that lies between the doctor and the playful. It comprises a series of disparate uses, such as the strengthening of pleasure in a multiplicity of activities ranging from food to sex, an enhanced ability to approach music and art, and also the ways in which catalyzes the new ideas and creativity. This is the kind of uses less appreciated or understood by those who do not smoke. It may also be possible that some people who use or have used marijuana are not aware of some of these possibilities of strengthening, if not the majority. This may be especially true for young people who are mostly interested in substance because it promotes the sociability, fun, playfulness. All are aware of the properties psicofarmacologicamente induced, such as increased appetite. It is a very common and manifests itself with the "nibble": can be a problem for consumers frequent who have difficulty in controlling the weight, but is a boon for those who suffer serious loss of appetite, as AIDS patients. For the most part these capacities of strengthening are not simple manifestations of inherent psicofarmacologiche properties of cannabis; some require some degree of learning, to develop. Anyone who wants to learn how to use the hemp in all of these modes, must first of all to know these possibilities, and then explore them and accumulate experience". Sees a future from drug for cannabis? "I doubt that it will be developed as a medicament. A future could be the production of cannabinoid analogs exist in nature, that perhaps for some patients may be more effective than the cannabis and will be able to completely eliminate the effect psicoattivo. But the pharmaceutical manufacturers will support their costs only in some cases because they are more hemp, even if it is illegal. The number of arrests for marijuana has now reached 800 thousand in the USA yet patients continue to risk using cannabis as medicine. For the pharmaceutical would be a lost war in departure. For all the reasons that we explained: the drugs are less effective of natural plant and cost more". Since 2006 in Italy Doctors may prescribe preparations, to be set up by the pharmacist in the pharmacy, using dronabinol or active substance-based vegetable cannabis for medical use, i.e. the active substance which is obtained from the inflorescences of cannabis grown behind authorization of a national body for cannabis, dried and milled, to assume the form of decoction or inhalation with suitable vaporizer. From 2013 in Italy is also prescrivibile by neurologists a registered product as a medicinal product with a basis of extracts of cannabis to reduce the painful spasm in multiple sclerosis (SativexR). The Sativex, whose active ingredient is a vegetable preparation consisting of a mixture of two extracts of Cannabis sativa, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) was authorised in Italy in April 2013 and was classified for the purposes of supply as medicinal product subject to restricted medical prescription, to renew from time to time, sellable to the public on the prescription of hospital centers or specialists - neurologist. If this active ingredient was available, in masterful prescription should be taken into account as indicated in the notes to Table 4 of the Official Pharmacopoeia: preparations masterful at the base of the active principles contained in medicinal products of industrial origin and subject to restrictive recipe according to art. 92, 93 and 94 of the Legislative Decree of 24 April 2006, n. 219 and successive amendments may be prepared only under the conditions laid down in the marketing authorisations for medicinal products industrial correspondents. assume for sublingual administration, and although it acts faster than Marinol, which takes an hour and a half to two hours, always requires more time than that of smoked marijuana. In addition, given its unpleasant flavor, many patients do not may keep under the language for the time necessary to its absorption". And with regard to the safety? "In effect, the new derivatives may be much less sure of marijuana to smoke, because it will be possible to ingerirne quan- A Conference of Democratic Member Maurice Hinchey in favor of therapeutic marijuhana, Washington, May 2005. Titativi higher than needed. Any new derivative must have a "safety index acceptable". In the case of marijuana this index is unknown because it has never caused a death by overdose. It is estimated on the basis of extrapolations from animal data, which is an almost non-existent 20.000-40.000 [This digit indicates the ratio between the lethal dose and the therapeutic dose: more is high, the more the drug is considered safe, ndr.]. It is unlikely that the index of safety of a new derivative could be higher ". But you can not delete the effects psychoactive? "I am not convinced that the therapeutic benefits of hemp can always be separated from its psychoactive effects. I do not believe that this is desirable. There is to say that anyone who smokes cannabis frequently to reduce a chronic pain or a high intra-ocular pressure will have a "high" very limited or non-existent. Many patients suffering from serious chronic diseases report that cannabis makes them feel better in general and notice a slight improvement of mood. But if there really is some difference in dosage between the alleviation of symptoms and the effect psicoattivo, then it is important that patients have the possibility of dosing the amount of cannabis they need, and this is only possible by smoking it. For those who do not like the effect psicoattivo, you can always develop a derivative of cannabis without them". She also speaks of a field enhancement of human faculty. What are you referring to? "This is a field of action of cannabis that lies between the doctor and the playful. It comprises a series of disparate uses, such as the strengthening of pleasure in a multiplicity of activities ranging from food to sex, an enhanced ability to approach music and art, and also the ways in which catalyzes the new ideas and creativity. This is the kind of uses less appreciated or understood by those who do not smoke. It may also be possible that some people who use or have used marijuana are not aware of some of these possibilities of strengthening, if not the majority. This may be especially true for young people who are mostly interested in substance because it promotes the sociability, fun, playfulness. All are aware of the properties psicofarmacologicamente induced, such as increased appetite. It is a very common and manifests itself with the "nibble": can be a problem for consumers frequent who have difficulty in controlling the weight, but is a boon for those who suffer serious loss of appetite, as AIDS patients. For the most part these capacities of strengthening are not simple manifestations of inherent psicofarmacologiche properties of cannabis; some require some degree of learning, to develop. Anyone who wants to learn how to use the hemp in all of these modes, must first of all to know these possibilities, and then explore them and accumulate experience". Sees a future from drug for cannabis? "I doubt that it will be developed as a medicament. A future could be the production of cannabinoid analogs exist in nature, that perhaps for some patients may be more effective than the cannabis and will be able to completely eliminate the effect psicoattivo. But the pharmaceutical manufacturers will support their costs only in some cases because they are more hemp, even if it is illegal. The number of arrests for marijuana has now reached 800 thousand in the USA yet patients continue to risk using cannabis as medicine. For the pharmaceutical would be a lost war in departure. For all the reasons that we explained: the drugs are less effective of natural plant and cost more". Since 2006 in Italy Doctors may prescribe preparations, to be set up by the pharmacist in the pharmacy, using dronabinol or active substance-based vegetable cannabis for medical use, i.e. the active substance which is obtained from the inflorescences of cannabis grown behind authorization of a national body for cannabis, dried and milled, to assume the form of decoction or inhalation with suitable vaporizer. From 2013 in Italy is also prescrivibile by neurologists a registered product as a medicinal product with a basis of extracts of cannabis to reduce the painful spasm in multiple sclerosis (SativexR). The Sativex, whose active ingredient is a vegetable preparation consisting of a mixture of two extracts of Cannabis sativa, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) was authorised in Italy in April 2013 and was classified for the purposes of supply as medicinal product subject to restricted medical prescription, to renew from time to time, sellable to the public on the prescription of hospital centers or specialists - neurologist. If this active ingredient was available, in masterful prescription should be taken into account as indicated in the notes to Table 4 of the Official Pharmacopoeia: preparations masterful at the base of the active principles contained in medicinal products of industrial origin and subject to restrictive recipe according to art. 92, 93 and 94 of the Legislative Decree of 24 April 2006, n. 219 and successive amendments may be prepared only under the conditions laid down in the marketing authorisations for medicinal products industrial correspondents. assume for sublingual administration, and although it acts faster than Marinol, which takes an hour and a half to two hours, always requires more time than that of smoked marijuana. In addition, given its unpleasant flavor, many patients do not may keep under the language for the time necessary to its absorption". And with regard to the safety? "In effect, the new derivatives may be much less sure of marijuana to smoke, because it will be possible to ingerirne quan- A Conference of Democratic Member Maurice Hinchey in favor of therapeutic marijuhana, Washington, May 2005. Titativi higher than needed. Any new derivative must have a "safety index acceptable". In the case of marijuana this index is unknown because it has never caused a death by overdose. It is estimated on the basis of extrapolations from animal data, which is an almost non-existent 20.000-40.000 [This digit indicates the ratio between the lethal dose and the therapeutic dose: more is high, the more the drug is considered safe, ndr.]. It is unlikely that the index of safety of a new derivative could be higher ". But you can not delete the effects psychoactive? "I am not convinced that the therapeutic benefits of hemp can always be separated from its psychoactive effects. I do not believe that this is desirable. There is to say that anyone who smokes cannabis frequently to reduce a chronic pain or a high intra-ocular pressure will have a "high" very limited or non-existent. Many patients suffering from serious chronic diseases report that cannabis makes them feel better in general and notice a slight improvement of mood. But if there really is some difference in dosage between the alleviation of symptoms and the effect psicoattivo, then it is important that patients have the possibility of dosing the amount of cannabis they need, and this is only possible by smoking it. For those who do not like the effect psicoattivo, you can always develop a derivative of cannabis without them". She also speaks of a field enhancement of human faculty. What are you referring to? "This is a field of action of cannabis that lies between the doctor and the playful. It comprises a series of disparate uses, such as the strengthening of pleasure in a multiplicity of activities ranging from food to sex, an enhanced ability to approach music and art, and also the ways in which catalyzes the new ideas and creativity. This is the kind of uses less appreciated or understood by those who do not smoke. It may also be possible that some people who use or have used marijuana are not aware of some of these possibilities of strengthening, if not the majority. This may be especially true for young people who are mostly interested in substance because it promotes the sociability, fun, playfulness. All are aware of the properties psicofarmacologicamente induced, such as increased appetite. It is a very common and manifests itself with the "nibble": can be a problem for consumers frequent who have difficulty in controlling the weight, but is a boon for those who suffer serious loss of appetite, as AIDS patients. For the most part these capacities of strengthening are not simple manifestations of inherent psicofarmacologiche properties of cannabis; some require some degree of learning, to develop. Anyone who wants to learn how to use the hemp in all of these modes, must first of all to know these possibilities, and then explore them and accumulate experience". Sees a future from drug for cannabis? "I doubt that it will be developed as a medicament. A future could be the production of cannabinoid analogs exist in nature, that perhaps for some patients may be more effective than the cannabis and will be able to completely eliminate the effect psicoattivo. But the pharmaceutical manufacturers will support their costs only in some cases because they are more hemp, even if it is illegal. The number of arrests for marijuana has now reached 800 thousand in the USA yet patients continue to risk using cannabis as medicine. For the pharmaceutical would be a lost war in departure. For all the reasons that we explained: the drugs are less effective of natural plant and cost more". Since 2006 in Italy Doctors may prescribe preparations, to be set up by the pharmacist in the pharmacy, using dronabinol or active substance-based vegetable cannabis for medical use, i.e. the active substance which is obtained from the inflorescences of cannabis grown behind authorization of a national body for cannabis, dried and milled, to assume the form of decoction or inhalation with suitable vaporizer. From 2013 in Italy is also prescrivibile by neurologists a registered product as a medicinal product with a basis of extracts of cannabis to reduce the painful spasm in multiple sclerosis (SativexR). The Sativex, whose active ingredient is a vegetable preparation consisting of a mixture of two extracts of Cannabis sativa, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) was authorised in Italy in April 2013 and was classified for the purposes of supply as medicinal product subject to restricted medical prescription, to renew from time to time, sellable to the public on the prescription of hospital centers or specialists - neurologist. If this active ingredient was available, in masterful prescription should be taken into account as indicated in the notes to Table 4 of the Official Pharmacopoeia: preparations masterful at the base of the active principles contained in medicinal products of industrial origin and subject to restrictive recipe according to art. 92, 93 and 94 of the Legislative Decree of 24 April 2006, n. 219 and successive amendments may be prepared only under the conditions laid down in the marketing authorisations for medicinal products industrial correspondents. assume for sublingual administration, and although it acts faster than Marinol, which takes an hour and a half to two hours, always requires more time than that of smoked marijuana. In addition, given its unpleasant flavor, many patients do not may keep under the language for the time necessary to its absorption". And with regard to the safety? "In effect, the new derivatives may be much less sure of marijuana to smoke, because it will be possible to ingerirne quan- A Conference of Democratic Member Maurice Hinchey in favor of therapeutic marijuhana, Washington, May 2005. Titativi higher than needed. Any new derivative must have a "safety index acceptable". In the case of marijuana this index is unknown because it has never caused a death by overdose. It is estimated on the basis of extrapolations from animal data, which is an almost non-existent 20.000-40.000 [This digit indicates the ratio between the lethal dose and the therapeutic dose: more is high, the more the drug is considered safe, ndr.]. It is unlikely that the index of safety of a new derivative could be higher ". But you can not delete the effects psychoactive? "I am not convinced that the therapeutic benefits of hemp can always be separated from its psychoactive effects. I do not believe that this is desirable. There is to say that anyone who smokes cannabis frequently to reduce a chronic pain or a high intra-ocular pressure will have a "high" very limited or non-existent. Many patients suffering from serious chronic diseases report that cannabis makes them feel better in general and notice a slight improvement of mood. But if there really is some difference in dosage between the alleviation of symptoms and the effect psicoattivo, then it is important that patients have the possibility of dosing the amount of cannabis they need, and this is only possible by smoking it. For those who do not like the effect psicoattivo, you can always develop a derivative of cannabis without them". She also speaks of a field enhancement of human faculty. What are you referring to? "This is a field of action of cannabis that lies between the doctor and the playful. It comprises a series of disparate uses, such as the strengthening of pleasure in a multiplicity of activities ranging from food to sex, an enhanced ability to approach music and art, and also the ways in which catalyzes the new ideas and creativity. This is the kind of uses less appreciated or understood by those who do not smoke. It may also be possible that some people who use or have used marijuana are not aware of some of these possibilities of strengthening, if not the majority. This may be especially true for young people who are mostly interested in substance because it promotes the sociability, fun, playfulness. All are aware of the properties psicofarmacologicamente induced, such as increased appetite. It is a very common and manifests itself with the "nibble": can be a problem for consumers frequent who have difficulty in controlling the weight, but is a boon for those who suffer serious loss of appetite, as AIDS patients. For the most part these capacities of strengthening are not simple manifestations of inherent psicofarmacologiche properties of cannabis; some require some degree of learning, to develop. Anyone who wants to learn how to use the hemp in all of these modes, must first of all to know these possibilities, and then explore them and accumulate experience". Sees a future from drug for cannabis? "I doubt that it will be developed as a medicament. A future could be the production of cannabinoid analogs exist in nature, that perhaps for some patients may be more effective than the cannabis and will be able to completely eliminate the effect psicoattivo. But the pharmaceutical manufacturers will support their costs only in some cases because they are more hemp, even if it is illegal. The number of arrests for marijuana has now reached 800 thousand in the USA yet patients continue to risk using cannabis as medicine. For the pharmaceutical would be a lost war in departure. For all the reasons that we explained: the drugs are less effective of natural plant and cost more". Since 2006 in Italy Doctors may prescribe preparations, to be set up by the pharmacist in the pharmacy, using dronabinol or active substance-based vegetable cannabis for medical use, i.e. the active substance which is obtained from the inflorescences of cannabis grown behind authorization of a national body for cannabis, dried and milled, to assume the form of decoction or inhalation with suitable vaporizer. From 2013 in Italy is also prescrivibile by neurologists a registered product as a medicinal product with a basis of extracts of cannabis to reduce the painful spasm in multiple sclerosis (SativexR). The Sativex, whose active ingredient is a vegetable preparation consisting of a mixture of two extracts of Cannabis sativa, cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) was authorised in Italy in April 2013 and was classified for the purposes of supply as medicinal product subject to restricted medical prescription, to renew from time to time, sellable to the public on the prescription of hospital centers or specialists - neurologist. If this active ingredient was available, in masterful prescription should be taken into account as indicated in the notes to Table 4 of the Official Pharmacopoeia: preparations masterful at the base of the active principles contained in medicinal products of industrial origin and subject to restrictive recipe according to art. 92, 93 and 94 of the Legislative Decree of 24 April 2006, n. 219 and successive amendments may be prepared only under the conditions laid down in the marketing authorisations for medicinal products industrial correspondents.